Cathie Wood
VERV

Cathie Wood’s Verve Therapeutics VERV Stock Holding History

Cathie Wood’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,936,063
Closed -$17.1M – 196
2024
Q2 		$14.3M Sell
2,936,063
-3,104,413
-51% -$19.5M 0.13% 83
2024
Q1 		$80.2M Sell
6,040,476
-984,640
-14% -$13.1M 0.56% 35
2023
Q4 		$97.9M Buy
7,025,116
+1,824,549
+35% +$22.6M 0.58% 33
2023
Q3 		$69M Buy
5,200,567
+49,716
+1% +$801K 0.53% 35
2023
Q2 		$96.6M Buy
5,150,851
+668,760
+15% +$11.1M 0.64% 32
2023
Q1 		$64.6M Buy
4,482,091
+116,261
+3% +$2.28M 0.44% 36
2022
Q4 		$84.5M Buy
4,365,830
+971,971
+29% +$25.8M 0.73% 26
2022
Q3 		$117M Buy
3,393,859
+1,359,735
+67% +$43.4M 0.81% 28
2022
Q2 		$30.8M Buy
2,034,124
+347,179
+21% +$5.38M 0.18% 74
2022
Q1 		$38.5M Buy
1,686,945
+287,400
+21% +$8.21M 0.16% 79
2021
Q4 		$51.6M Buy
1,399,545
+131,840
+10% +$5.54M 0.16% 85
2021
Q3 		$59.6M Buy
1,267,705
+719,316
+131% +$42.3M 0.14% 103
2021
Q2 		$33M Buy
+548,389
New +$22.8M 0.06% 149

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Cathie Wood's VERV Position: Q3 2024 in Review

Cathie Wood sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 2,936,063 shares — an estimated $17.1M sold.

Cathie Wood first reported a position in VERV in Q2 2021 and held it in 13 quarters. The position peaked at $117M in Q3 2022. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • Cathie Wood reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cathie Wood sold 2,936,063 Verve Therapeutics shares in Q3 2024, an estimated $17.1M.
  • Cathie Wood first reported a position in Verve Therapeutics in Q2 2021 and held it in 13 quarters.
  • Cathie Wood's Verve Therapeutics position peaked at $117M in Q3 2022.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on ARK Investment Management's 13F filing for Q3 2024, filed 31 Oct 2024.